Integrated Simulation Framework for Toxicity, Dose Intensity, Disease Progression, and Cost Effectiveness for Castration‐Resistant Prostate Cancer Treatment With Eribulin

Publisher： John Wiley & Sons Inc

E-ISSN： 2163-8306|4|7|374-385

ISSN： 2163-8306

Source： Cpt: Pharmacometrics & Systems Pharmacology, Vol.4, Iss.7, 2015-08, pp. : 374-385

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Disease Progression/Clinical Outcome Model for Castration‐Resistant Prostate Cancer in Patients Treated With Eribulin

By  

Cpt: Pharmacometrics & Systems Pharmacology, Vol. 4, Iss. 7, 2015-08 ,pp. : 386-395

John Wiley & Sons Inc

Access to resources Recommend Favorite

Somatostatin analog lanreotide in the treatment of castration-resistant prostate cancer (CRPC)

By Mitsogiannis Iraklis C   Skolarikos Andreas   Deliveliotis Charalambos  

Expert Opinion on Pharmacotherapy, Vol. 10, Iss. 3, 2009-02 ,pp. : 493-501

Informa Healthcare

Access to resources Recommend Favorite

New agents and strategies for the hormonal treatment of castration-resistant prostate cancer

By Sharifi Nima  

Expert Opinion on Investigational Drugs, Vol. 19, Iss. 7, 2010-07 ,pp. : 837-846

Informa Healthcare

Access to resources Recommend Favorite

Cholesterol as a Potential Target for Castration-Resistant Prostate Cancer

By Twiddy Alexis   Leon Carlos   Wasan Kishor  

Pharmaceutical Research, Vol. 28, Iss. 3, 2011-03 ,pp. : 423-437

Springer Publishing Company

Access to resources Recommend Favorite

Sipuleucel-T: In Metastatic Castration-Resistant Prostate Cancer

By Plosker Greg L.  

Drugs, Vol. 71, Iss. 1, 2011-01 ,pp. : 101-108

Adis International

Access to resources Recommend Favorite